Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


First published online January 19, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-0487v1
24/5/1280    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shan, X.
Right arrow Articles by Liu, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shan, X.
Right arrow Articles by Liu, R.
Submitted on October 2, 2005
Accepted on January 7, 2006

Tissue-Specific Stem Cells

Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of MPTP-induced Parkinson's disease-like mice

Xiaoyang Shan 1, Liying Chi 1, Michael Bishop 1, Chun Luo 1, Lindsey Lien 1, Zheng Zhang 1, Rugao Liu 1*

1 Department of Anatomy and Cell Biology, University of North Dakota School of Medicine, Grand Forks, North Dakota

* To whom correspondence should be addressed. E-mail: rliu{at}medicine.nodak.edu.


   Abstract

Research reports on de novo neurogenesis, particularly dopaminergic (DA) neurogenesis in the adult mammalian substantia nigra (SN) remain very controversial. For this reason, we utilized the nestin second-intron enhancer controlled LacZ reporter (pNes-LacZ) transgenic mouse model coupled with MPTP lesion system to investigate whether there are neurogenesis and DA neurogenesis in the SN of the adult normal and Parkinson's disease (PD)-like mice. First, we demonstrated the presence of neural progenitor cells (NPCs), basal levels of neurogenesis, and DA neurogenesis in the normal adult mouse SN. Second, we showed there is not only a significant increase in the number of NPCs, but also a dramatic increase of neurogenesis from the NPCs in the SN and the midline region adjacent to the SN of the PD-like mice, compared with that of normal controls. More importantly, we also demonstrated there is an increase of DA neurogenesis in the SN of the MPTP lesioned mice. Third, we showed that the increased DA neurogenesis in the MPTP lesioned mice was derived from the NPCs and BrdU positive cells, suggesting multiple stem cell lineages may contribute to the enhanced neurogenesis in the adult SN. Taken together, these results establish that there are basal levels, albeit low, and increased levels of de novo neurogenesis and DA neurogenesis in the SN of the adult normal and PD-like mice respectively. The increased NPCs in the MPTP lesioned mice further suggest that experimental approaches to promote de novo neurogenesis may provide an effective therapy for PD by functional replacement of degenerated DAs.




This article has been cited by other articles:


Home page
Therapeutic Advances in Neurological DisordersHome page
B. Winner, D. M. Vogt-Weisenhorn, C. D. Lie, I. Blumcke, and J. Winkler
Review: Cellular repair strategies in Parkinson's disease
Therapeutic Advances in Neurological Disorders, January 1, 2009; 2(1): 51 - 60.
[Abstract] [PDF]


Home page
Stem CellsHome page
A. Hermann and A. Storch
Endogenous Regeneration in Parkinson's Disease: Do We Need Orthotopic Dopaminergic Neurogenesis?
Stem Cells, November 1, 2008; 26(11): 2749 - 2752.
[Full Text] [PDF]


Home page
Stem CellsHome page
M. Geraerts, O. Krylyshkina, Z. Debyser, and V. Baekelandt
Concise Review: Therapeutic Strategies for Parkinson Disease Based on the Modulation of Adult Neurogenesis
Stem Cells, February 1, 2007; 25(2): 263 - 270.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. Timmer, K. Cesnulevicius, C. Winkler, J. Kolb, E. Lipokatic-Takacs, J. Jungnickel, and C. Grothe
Fibroblast Growth Factor (FGF)-2 and FGF Receptor 3 Are Required for the Development of the Substantia Nigra, and FGF-2 Plays a Crucial Role for the Rescue of Dopaminergic Neurons after 6-Hydroxydopamine Lesion
J. Neurosci., January 17, 2007; 27(3): 459 - 471.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. M. Van Kampen and C. B. Eckman
Dopamine D3 receptor agonist delivery to a model of Parkinson's disease restores the nigrostriatal pathway and improves locomotor behavior.
J. Neurosci., July 5, 2006; 26(27): 7272 - 7280.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 2006 by AlphaMed Press.